Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Healx gets $56mm via Series B

Executive Summary

Artificial intelligence company Healx Ltd. (developing therapies for rare diseases) raised $56mm in its Series B financing led by Atomico, which was joined by other new backers Intel Capital, Global Brain, and btov Partners, and returning shareholders Balderton Capital, Amadeus Capital Partners, and Jonathan Milner. Healx will use the proceeds for pipeline development and to launch its Rare Treatment Accelerator program, which uses AI to help in the discovery of new treatments for rare diseases, such as fragile X syndrome, through collaboration. They seek to identify clinic-ready treatments within 24 months.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies